Learn more

NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM

Overview
  • Total Patents
    83
  • GoodIP Patent Rank
    17,378
  • Filing trend
    ⇧ 166.0%
About

NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM has a total of 83 patent applications. It increased the IP activity by 166.0%. Its first patent ever was published in 2015. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are UNIV OKLAHOMA STATE, UNIV KEIO and VERENIGING HET NL KANKER I.

Patent filings per year

Chart showing NATIONAL UNIV CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEMs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Shamoto Eiji 9
#2 Hori Katsutoshi 6
#3 Hayasaka Takehiro 4
#4 Ueda Hiroshi 4
#5 Kurachi Ryo 4
#6 Torimoto Tsukasa 4
#7 Takada Hiroaki 4
#8 Kameyama Tatsuya 4
#9 Igasaki Yasunori 3
#10 Matsumoto Hiroko 3

Latest patents

Publication Filing date Title
WO2021060311A1 Method for detecting brain tumor
WO2021060192A1 Power storage device and method for manufacturing electrode for power storage device
WO2021054321A1 Semiconductor device and method for manufacturing same
WO2021049671A1 Body fluid extract containing micro rna
WO2021045235A1 Novel microorganism having high ability to degrade oil at low temperature
WO2021045234A1 Novel esterase for decomposing trans fatty acid-containing ester
WO2021045224A1 Predicting immune-related adverse events during cancer immunotherapy and the like
WO2021039879A1 Nucleic acid medicine for targeting gastric cancer molecule
WO2021044907A1 Thermic fluid state computation apparatus
WO2021039727A1 Semiconductor nanoparticles, production method for same, and light-emitting device
WO2021039598A1 Rna action inhibitor and use thereof
WO2021049257A1 Skiving device and skiving method
WO2021029334A1 Rna interference agent, multiple chemically modified oligonucleotide, and use thereof
WO2021025104A1 Plant rna
WO2021025102A1 Medicine for preventing and/or treating insulin-dependent diabetes mellitus
WO2021024897A1 Combination drug for treating malignant tumor, pharmaceutical composition for treating malignant tumor, and pharmaceutical composition for malignant tumor treatment
WO2021020425A1 Sintered compact manufacturing method and sintered compact manufacturing device
WO2021010481A1 Adhesive protein
WO2021010482A1 Separated peptide
WO2021014812A1 Treatment for fibroblastic or myofibroblastic tumor and disease